1. Medtech Insight
  2. >>Policy & Regulation

ADA 2020: Abbott Expects CGM To Reduce Insulin Needed For Type 2 Diabetes

 
• By Catherine Longworth

Research presented at this year’s virtual American Diabetes Association meeting demonstrated the benefits of continuous glucose monitoring for those with type 2 diabetes not taking insulin. Mahmood Kazemi, divisional VP for global medical and scientific affairs at Abbott’s diabetes care tells Medtech Insight how he sees CGM technology transforming the future of diabetes management.

Diabetes

For individuals with type 2 diabetes, continuous glucose monitoring (CGM) devices may one day become the standard of care, according to Abbott Laboratories Inc.

At this year’s American Diabetes Association (ADA) virtual meeting, the company presented data to support the use of CGM systems in individuals with type 2 diabetes, whether they use insulin or not

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation